2064
document
Comparison of antiresorptive activities of ipriflavone , an isoflavone derivative , and elcatonin , an eel carbocalcitonin . Thirty postmenopausal women with reduced bone mineral density were divided randomly into two groups based on the chronological sequence of their first visit to the Osteoporosis Clinic of Katsuragi Hospital . Group I was given 600 mg ipriflavone orally daily and group II was weekly injected intramuscularly with 20 units elcatonin , Asu1-7 eel calcitonin ( carbocalcitonin ) . Lumbar spine BMD was measured by dual-energy X-ray absorptiometry , and trabecular bone mineral density at the distal radius , cortical bone density , and relative cortical volume at the radial diaphysis by peripheral computed tomography before the beginning of the study and at the 4th , 8th , and 12th month . Markers of bone metabolism -- serum total alkaline phosphatase , bone-specific alkaline phosphatase , tartrate-resistant acid phosphatase , osteocalcin , intact osteocalcin , PICP and ICTP , and urinary pyridinoline , deoxypyridinoline , and calcium/creatinine ( Ca/Cr ) -- were also measured at the same interval . Plasma parathyroid hormone ( PTH ) and calcitonin ( CT ) were measured at the same time . Radial trabecular bone density showed a significantly higher rate of increase in group I ( ipriflavone group ) than in group II ( elcatonin group ) at the 4th month , whereas lumbar spine BMD showed more pronounced increase in the elcatonin group than in the ipriflavone group throughout the study period . Bone metabolism markers tended to decline in both groups . Total and intact osteocalcin showed a significant fall from the baseline throughout the study period only in the ipriflavone group . Urine pyridinoline and deoxypyridinoline showed a significant fall from the baseline at the 12th month only in the ipriflavone group . On comparing bone gainers with increase of lumbar spine BMD by 2 % or more with bone losers with a decrease by 2 % or more , only urine Ca/Cr was significantly different , lower in the former than in the latter , despite the general tendency for bone resorption markers to decrease in bone gainers and to increase in bone losers .
2065
Intervention_Pharmacological
ipriflavone
2066
Intervention_Pharmacological
isoflavone
2067
Intervention_Pharmacological
elcatonin
2068
Intervention_Pharmacological
eel carbocalcitonin
2069
Intervention_Pharmacological
ipriflavone
2070
Intervention_Pharmacological
elcatonin , Asu1-7 eel calcitonin ( carbocalcitonin ) .
2071
Outcome_Physical
Lumbar spine BMD
2072
Outcome_Physical
trabecular bone mineral density
2073
Outcome_Physical
cortical bone density
2074
Outcome_Physical
relative cortical volume
2075
Outcome_Physical
Markers of bone metabolism -- serum total alkaline phosphatase , bone-specific alkaline phosphatase , tartrate-resistant acid phosphatase , osteocalcin , intact osteocalcin , PICP and ICTP , and urinary pyridinoline , deoxypyridinoline , and calcium/creatinine ( Ca/Cr )
2076
Outcome_Physical
Plasma parathyroid hormone ( PTH ) and calcitonin ( CT )
2077
Outcome_Physical
Radial trabecular bone density
2078
Outcome_Physical
lumbar spine BMD
2079
Outcome_Physical
Bone metabolism markers
2080
Outcome_Physical
Total and intact osteocalcin
2081
Outcome_Physical
Urine pyridinoline and deoxypyridinoline
2082
Outcome_Physical
lumbar spine BMD
2083
Outcome_Physical
urine Ca/Cr
2084
Participant_Sample-size
Thirty
2085
Participant_Condition
postmenopausal
2086
Participant_Sex
women
2087
Participant_Condition
reduced bone mineral density
2088
Participant_Condition
Osteoporosis